ImmunityBio Shares Fall 19% on Revenue Miss, Going-Concern Warning

ImmunityBio shares fell 19% to US$6.97 after revenue missed consensus and a US$184.6 million loss widened. ANKTIVA sales rose 53%, but a going-concern warning dominated.